Allucent (US)
Allucent (US) is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
A Phase 2 Randomized, Double-blind Placebo-Controlled Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety and Efficacy of WIN378 in Adult Participants with Moderate or Severe Asthma (the POLARIS trial)
Sponsor Windward Bio AG
- Start (EU)
- Latest update
- Estimated end
4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome
Sponsor Stealth Biotherapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer
Sponsor Puma Biotechnology Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
Sponsor Exelixis Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Sponsor Eidos Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
Sponsor Eidos Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)
Sponsor Eidos Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Sponsor Exelixis Inc.
- Start (EU)
- Latest update
- Estimated end
A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Sponsor Y-mAbs Therapeutics A/S
- Start (EU)
- Latest update
- Estimated end
A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodect in Adult and Adolescent Patients with Tourette Syndrome – Allevia 2
Sponsor Noema Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction
Sponsor Tenax Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Allucent (US)?
The 2026-10-09 snapshot links Allucent (US) to 11 distinct CTIS trials. Recorded services include Statistical analysis, Data Flow Mapping for GDPR, Data management, Medical writing, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Allucent (US)?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Cardiology, Genetic and Congenital Disorders, Respiratory. Recorded phases include Phase 3, Phase 2, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Allucent (US) conducted?
The linked trials record locations in 16 countries, including Spain, France, Germany, Italy, Belgium. These are trial locations, not confirmed office locations or countries where Allucent (US) delivered services.
What can this page tell me about Allucent (US)'s trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Allucent (US). Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Allucent (US) LLC